Details of Disease

General Information of Disease (ID: DIS4IMNF)

Disease Name	Gastrinoma
Synonyms	gastrinoma; ZES; pancreatic ulcerogenic tumor syndrome; Z E syndrome; pancreatic ulcerogenic tumour syndrome; Z-E syndrome; Zollinger-Ellison syndrome (disease); Zollinger Ellison syndrome; Zollinger-Ellison syndrome
Disease Class	2C10: Pancreatic cancer
Definition	Zollinger-Ellison syndrome (ZES) is characterized by severe peptic disease (ulcers/esophageal disease) caused by hypergastrinemia secondary to a gastrinoma resulting in increased gastric acid secretion.
Disease Hierarchy	DIS9RZ96: Neoplastic syndrome DISZOMTV: Gastrin secretion abnormality DIS4IMNF: Gastrinoma
ICD Code	ICD-11 ICD-11: 2C10.1
Disease Identifiers	MONDO ID MONDO_0019610 UMLS CUI C0043515 MedGen ID 53129 HPO ID HP:0002044 Orphanet ID 913 SNOMED CT ID 53132006

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cimetidine	DMH61ZB	Approved	Small molecular drug	[1]
Esomeprazole	DM7BN0X	Approved	Small molecular drug	[2]
Famotidine	DMRL3AB	Approved	Small molecular drug	[3]
Lansoprazole	DMXYLQ3	Approved	NA	[4]
Omeprazole	DM471KJ	Approved	Small molecular drug	[5]
Pantoprazole	DMSVOCZ	Approved	Small molecular drug	[6]
Rabeprazole	DMMZXIW	Approved	Small molecular drug	[7]
Ranitidine	DM0GUSX	Approved	Small molecular drug	[8]
Secretin	DMDKE4N	Approved	Small molecular drug	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 3 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GAST	TT4LRVO	Strong	Altered Expression	[10]
PPY	TTIB95A	Strong	Altered Expression	[11]
SCT	TTOBVIN	Definitive	Biomarker	[12]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MEN1	OTN6U6V0	Strong	Biomarker	[13]
SCTR	OTC80IMR	Strong	Altered Expression	[12]
------------------------------------------------------------------------------------

References

1	Cimetidine FDA Label
2	Esomeprazole FDA Label
3	Famotidine FDA Label
4	Lansoprazole FDA Label
5	Omeprazole FDA Label
6	Pantoprazole FDA Label
7	Rabeprazole FDA Label
8	Ranitidine FDA Label
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3644).
10	Case report: optimal tumor cytoreduction and octreotide with durable disease control in a patient with MEN-1 and Zollinger-Ellison syndrome-over a decade of follow-up.World J Surg Oncol. 2019 Dec 9;17(1):213. doi: 10.1186/s12957-019-1758-6.
11	Serum levels of pancreatic polypeptide in Zollinger-Ellison syndrome, and hyperparthyroidism from families with multiple endocrine adenomatosis type I.Digestion. 1978;18(5-6):297-302. doi: 10.1159/000198216.
12	Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.J Clin Endocrinol Metab. 2007 Nov;92(11):4394-402. doi: 10.1210/jc.2007-0986. Epub 2007 Aug 21.
13	Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1.Best Pract Res Clin Endocrinol Metab. 2019 Oct;33(5):101318. doi: 10.1016/j.beem.2019.101318. Epub 2019 Aug 31.